Tango Therapeutics

TNGX · Nasdaq · United States

Share price · TNGX

$21.89-3.55 (-13.95%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.7M (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when TNGX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026+6.9%
  2. 23 Oct 2026-16.4%
  3. 21 Oct 2026+6.9%
  4. 22 Sep 2026+14.3%
  5. 18 Sep 2026-7.4%
  6. 9 Sep 2026+5.7%
  7. 8 Jun 2026+53.0%
  8. 15 May 2026-17.3%
  9. 5 Mar 2026+36.3%
  10. 26 Feb 2026-9.7%

Share of unusual movement by asset

For each asset, the share of TNGX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Vopimetostat
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—13%
Other company news (earnings, financing, releases naming no asset)—23%
Sessions with no dated event—65%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1/2
PRMT5Small molecule
Non-Small Cell Lung CancerGlioblastoma
Phase 1/2
PRMT5Small molecule
Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Discontinued programmes (2)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
March 2027 (1)
TNG456Phase 1/2Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer …
Est. primary completion 2027-03-31 · NCT06810544 · CT.gov ↗
What to watch
June 2027 (2)
VopimetostatPhase 1/2Locally Advanced Solid Tumor
Est. primary completion 2027-06 · NCT05732831 · CT.gov ↗
What to watch
VopimetostatPhase 1/2PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic …
Est. primary completion 2027-06 · NCT06922591 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
VopimetostatPhase 1/2PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic …
Est. primary completion 2031-11 · NCT07897734 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 June 2026Topline resultTNG462Vopimetostat (TNG462) plus daraxonrasib Phase 1/2 (NCT06922591): 92% objective response rate in MTAP-deleted pancreatic cancer (initial data)
Tango Therapeutics, Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$49M$87M+ $891M short-term inv.$68M-$37M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$37M$346M+ $668M short-term inv.$55M-$39M operating cash flowreport ↗
2026-Q1$0$34M$158M+ $222M short-term inv.$46M-$44M operating cash flowreport ↗
2025-Q3$54M$31M$58M+ $94M short-term inv.—-$31M operating cash flowreport ↗
2025-Q2$3.2M$33M$39M+ $142M short-term inv.$39M-$37M operating cash flowreport ↗
2025-Q1$5.4M$36M$58M+ $158M short-term inv.$40M-$42M operating cash flowreport ↗
2024-Q3$12M$33M$53M+ $240M short-term inv.$29M-$33M operating cash flowreport ↗
2024-Q2$20M$39M$52M+ $271M short-term inv.$26M-$24M operating cash flowreport ↗
2024-Q1$6.5M$38M$61M+ $282M short-term inv.$38M-$38M operating cash flowreport ↗
2023-Q3$11M$27M$59M+ $301M short-term inv.$22M-$31M operating cash flowreport ↗
2023-Q2$15M$29M$66M+ $245M short-term inv.$21M-$24M operating cash flowreport ↗
2023-Q1$5.8M$28M$57M+ $276M short-term inv.$28M-$35M operating cash flowreport ↗
2022-Q3$6.9M$29M$100M+ $293M short-term inv.$29M-$20M operating cash flowreport ↗
2022-Q2$5.8M$24M$105M+ $312M short-term inv.$25M-$32M operating cash flowreport ↗
2022-Q1$5.8M$24M$100M+ $350M short-term inv.$25M-$30M operating cash flowreport ↗
2021-Q3$6.8M$22M$205M+ $299M short-term inv.$20M-$42M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$62M$132M$112M+ $231M short-term inv.$25M-$139M operating cash flowreport ↗

Tango Therapeutics reported full-year 2025 revenue of $62.384M, up 48.3% YoY, with R&D expense of $132.165M, down 8.2% YoY. The company held $112.279M in cash and cash equivalents, or $343.1M including marketable securities, and recorded a full-year net loss of $101.6M, or $0.87 per share, compared with a net loss of $130.3M, or $1.19 per share, in the prior year.

Management guided to a cash runway into 2028. The company is on track to initiate a pivotal vopimetostat monotherapy study in second-line MTAP-deleted pancreatic cancer in 2026, with initial Phase 1/2 data from vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitors daraxonrasib and zoldonrasib also expected in 2026. Tango additionally entered a clinical supply agreement with Erasca to evaluate vopimetostat with ERAS-0015, and expects initial Phase 1/2 data for TNG456 in 2026. Corporate developments included the succession of Malte Peters as CEO, the appointment of Philippe Serrano as Chief Regulatory Officer, and the addition of Sung Lee to the board.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$42M$144M$70M+ $188M short-term inv.$33M-$132M operating cash flowreport ↗
2023-FY$37M$115M$66M+ $271M short-term inv.$25M-$118M operating cash flowreport ↗
2022-FY$25M$106M$60M+ $306M short-term inv.$27M-$109M operating cash flowreport ↗
2021-FY$37M$78M$143M+ $343M short-term inv.$15M-$60M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 31 sales ($8.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17Ketchum John B · directorOpen-market sale3,333$24.08$80KForm 4
2026-11-11Crystal Adam · President, R&DOption exercise5,000$2.91$15KForm 4
2026-11-11Crystal Adam · President, R&DOpen-market sale5,000$25.00$125KForm 4
2026-11-11Crystal Adam · President, R&DOption exercise (derivative)5,000——Form 4
2026-11-02Newcomb Jessica · Principal Accounting OfficerOpen-market sale5,571$22.28$124KForm 4
2026-11-02Crystal Adam · President, R&DOption exercise5,000$2.91$15KForm 4
2026-11-02Newcomb Jessica · Principal Accounting OfficerOpen-market sale1,460$22.98$34KForm 4
2026-11-02Crystal Adam · President, R&DOpen-market sale3,900$22.26$87KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 194 reporting institutions held 180.5M shares ($3.7B, 106.5% of shares outstanding).

#InstitutionSharesValue
1RTW INVESTMENTS, LP13,300,620$278.2M
2ADAGE CAPITAL PARTNERS GP, L.L.C.12,809,485$268.0M
3Boxer Capital Management, LLC10,876,219$227.5M
4TCG Crossover Management, LLC10,531,071$220.3M
5FMR LLC9,905,919$207.2M
6FARALLON CAPITAL MANAGEMENT LLC9,097,411$190.3M
7BlackRock, Inc.8,748,045$183.0M
8Woodline Partners LP8,000,013$167.4M
9Nextech Invest, Ltd.7,266,081$152.0M
10TRV GP IV, LLC6,374,574$133.4M
11Siren, L.L.C.5,657,105$118.3M
12VANGUARD CAPITAL MANAGEMENT LLC5,161,431$108.0M
13GOLDMAN SACHS GROUP INC5,076,392$106.2M
14STATE STREET CORP4,651,894$97.3M
15DEERFIELD MANAGEMENT COMPANY, L.P.4,146,813$86.8M